SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Drug Profile

SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics; SV-BR-1-GM-vaccine-BriaCell-Therapeutics; SV-BR1-GM-breast-cancer-vaccine-BriaCell-Therapeutics

Latest Information Update: 20 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wiseman Research Initiatives LLC
  • Developer BriaCell Therapeutics Corp; Saint Vincent Catholic Medical Centers; Wiseman Research Initiatives LLC
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Ovarian cancer

Most Recent Events

  • 19 Jul 2017 BriaCell expects to complete enrolment of first 10 patients in its phase I/II trial for Breast cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA by the end of September 2017
  • 15 Mar 2017 BriaCell Therapeutics initiates enrolment in a phase I/II trial for Breast cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Recurrent) in USA (NCT03066947)
  • 05 Jan 2017 BriaCell plans a clinical trial for Cancer (Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top